Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Linde PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.44 (market cap $29.60B), while Linde PLC trades at $486.6 (market cap $226.12B). The key difference: Linde PLC is far larger — about 7.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Linde PLC pays a 1.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LIN | |
|---|---|---|
Market Cap | $29.60B | $226.12B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $546.64 |
52-Week Low | $205.48 | $389.38 |
Enterprise Value | $27.56B | $249.24B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Linde (LIN) trades at $492.46, up 0.51% on the day, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.50 exceeding the $4.49 estimate (Zacks Investment Research, 2026-05-01). Revenue growth is steady, and profitability remains robust with a 20.43% net income margin. Analyst sentiment is overwhelmingly positive, with a consensus price target of $553.60.
The outlook for LIN is favorable due to its operational strength and dividend growth, though valuation multiples are elevated. Key risks include rising debt levels and macroeconomic pressures on industrial demand. The stock offers a compelling opportunity for long-term investors seeking quality industrial exposure, but near-term technical weakness may present entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
